Last updated: September 2, 2026
C1 esterase inhibitor (human) is a plasma-derived biologic used to treat or prevent hereditary angioedema (HAE). The U.S. market is concentrated in CSL Behring's Berinert and Haegarda and Takeda's Cinryze. Berinert is positioned mainly for acute attacks, while Haegarda and Cinryze are long-term prophylaxis products. The market has shifted from intravenous replacement therapy toward subcutaneous prophylaxis and oral kallikrein inhibition, increasing competitive pressure on older intravenous products.
Product-level revenue is not publicly disclosed by CSL Behring or Takeda. Financial analysis therefore depends on company segment results, product commentary, prescription data and market structure rather than audited sales for each C1 inhibitor.
What products contain C1 esterase inhibitor (human)?
The principal products are plasma-derived C1 esterase inhibitor replacement therapies.
| Product |
Company |
Active ingredient |
U.S. use |
Administration |
FDA approval |
| Berinert |
CSL Behring |
C1 esterase inhibitor, human |
Treatment of acute abdominal, facial or laryngeal HAE attacks |
Intravenous |
2009 |
| Cinryze |
Takeda, formerly Shire |
C1 esterase inhibitor, human |
Routine prophylaxis against HAE attacks |
Intravenous |
2008 |
| Haegarda |
CSL Behring |
C1 esterase inhibitor, human |
Routine prophylaxis against HAE attacks |
Subcutaneous |
2017 |
| Ruconest |
Pharming |
Recombinant C1 esterase inhibitor |
Treatment of acute HAE attacks |
Intravenous |
2014 |
| Takhzyro |
Takeda |
Lanadelumab |
Long-term HAE prophylaxis |
Subcutaneous |
2018 |
| Orladeyo |
BioCryst |
Berotralstat |
Long-term HAE prophylaxis |
Oral |
2020 |
Ruconest is not a human plasma-derived C1 esterase inhibitor. It is a recombinant product produced in transgenic rabbits and competes in the acute-attack segment rather than directly duplicating the manufacturing platform of Berinert, Cinryze or Haegarda.
How large is the C1 esterase inhibitor market?
The addressable market is driven by HAE prevalence, diagnosis rates, treatment duration and the proportion of patients receiving prophylaxis. HAE is rare, but treatment costs per patient are high because therapy is chronic or episodic and often requires specialty distribution.
The market has three economic segments:
- Acute treatment of breakthrough attacks.
- Long-term prophylaxis for patients with frequent or severe attacks.
- On-demand therapy retained by patients already receiving prophylaxis.
The commercial center of gravity has moved toward prophylaxis. Historical intravenous prophylaxis with Cinryze has faced erosion from Haegarda's subcutaneous delivery, Takhzyro's less frequent dosing and Orladeyo's oral administration. Acute treatment remains important because even patients on prophylaxis can experience breakthrough attacks.
Market growth is supported by:
- Better recognition of HAE and delayed diagnosis reduction.
- Increased use of long-term prophylaxis.
- Broader treatment of adolescents and patients with lower attack thresholds.
- Expansion of specialty pharmacy and home self-administration.
- Persistent high cost of untreated or emergency-treated attacks.
Market constraints include:
- Small diagnosed patient populations.
- High treatment cost and payer prior authorization.
- Plasma collection and fractionation capacity.
- Patient switching to non-C1-INH therapies.
- Competitive oral and monoclonal-antibody products.
- Reduced need for frequent intravenous administration.
What is the financial trajectory of Berinert, Cinryze and Haegarda?
Public company reporting indicates a mature but strategically important franchise rather than a separately reported high-growth product category.
CSL Behring
CSL Behring owns Berinert and Haegarda. CSL reports revenue by major business and therapeutic area, but it does not generally provide audited, product-level sales for each HAE product. The franchise benefits from CSL's plasma collection network, manufacturing scale and specialty commercial infrastructure.
Haegarda has the stronger structural growth profile within the human C1-INH category because it converts prophylaxis from intravenous infusion to subcutaneous self-administration. Berinert remains commercially relevant because acute attacks require rapid rescue treatment and because patients using prophylaxis may retain an acute therapy.
The financial trajectory is therefore mixed:
- Haegarda has a favorable mix profile but competes against Takhzyro and Orladeyo.
- Berinert has durable acute-use demand but faces competition from icatibant, ecallantide and Ruconest.
- The combined franchise is more defensive than high-growth.
- Revenue resilience depends on diagnosis expansion and treatment persistence rather than major price or volume expansion.
CSL's broader plasma-derived portfolio also creates manufacturing and supply advantages that smaller competitors cannot easily duplicate. The same infrastructure exposes the company to plasma collection costs, donor availability and fractionation economics.
Takeda
Takeda acquired Shire in 2019 and inherited Cinryze and other HAE assets. Cinryze has a weaker growth profile than Haegarda because it requires intravenous administration and competes against both subcutaneous and oral prophylaxis.
Takeda does not separately disclose Cinryze revenue in a way that permits a reliable standalone financial series. Its financial contribution is embedded in Takeda's rare-disease reporting. The product's strategic value is based on installed patients, physician familiarity and use in patients for whom intravenous C1-INH remains clinically appropriate.
Cinryze is exposed to greater substitution risk than Haegarda because:
- Haegarda offers subcutaneous administration with weight-based dosing.
- Takhzyro offers less frequent subcutaneous administration.
- Orladeyo eliminates injections for eligible patients.
- Payers can use step therapy or preferred-product policies.
Financial trajectory by product
| Product |
Near-term commercial direction |
Primary growth driver |
Main erosion risk |
| Berinert |
Stable to moderate pressure |
Acute attack treatment and diagnosis growth |
Competing acute therapies |
| Haegarda |
More favorable within C1-INH |
Subcutaneous prophylaxis and home use |
Takhzyro and Orladeyo |
| Cinryze |
Mature to declining |
Existing patient base and physician familiarity |
Route-of-administration disadvantage |
| Ruconest |
Niche |
Non-plasma-derived positioning and acute use |
Berinert and small patient base |
| Takhzyro |
Strong competitive position |
Convenient prophylaxis and high persistence |
Oral therapy and payer control |
| Orladeyo |
Growth-oriented |
Oral administration |
Efficacy, tolerability and payer restrictions |
How does human C1 esterase inhibitor compare with Takhzyro and Orladeyo?
Human C1-INH products replace a deficient regulatory protein. Takhzyro inhibits plasma kallikrein, and Orladeyo inhibits the same pathway through oral small-molecule therapy. The products compete clinically even though their mechanisms and regulatory classifications differ.
| Attribute |
Human C1-INH |
Takhzyro |
Orladeyo |
| Product type |
Plasma-derived biologic |
Monoclonal antibody |
Oral small molecule |
| Main role |
Acute treatment or prophylaxis, depending on product |
Long-term prophylaxis |
Long-term prophylaxis |
| Administration |
Intravenous or subcutaneous |
Subcutaneous |
Oral |
| Plasma dependence |
Yes |
No |
No |
| Main advantage |
Replacement therapy with established clinical use |
Infrequent dosing |
Convenience and no injection |
| Main commercial weakness |
Plasma supply and administration burden |
Injection and biologic cost |
Daily dosing and drug-interaction considerations |
The main competitive shift is not a direct price comparison. It is the reduction in treatment friction. Patients and payers increasingly value home administration, fewer doses and avoidance of intravenous access. This favors Haegarda over Cinryze but favors Takhzyro and Orladeyo over both products in many prophylaxis decisions.
When does C1 esterase inhibitor human lose exclusivity?
FDA biologic exclusivity and orphan-drug exclusivity are separate from patent protection.
| Product |
First U.S. approval |
Twelve-year biologic reference exclusivity |
Seven-year orphan exclusivity |
| Cinryze |
2008 |
Approximately 2020 |
Approximately 2015 |
| Berinert |
2009 |
Approximately 2021 |
Approximately 2016 |
| Haegarda |
2017 |
Approximately 2029 |
Approximately 2024 |
The dates are based on the original U.S. licensure and statutory exclusivity periods. They do not establish the date on which a competitor can launch. Patent term, regulatory review, pediatric exclusivity, manufacturing readiness and litigation can change the practical entry date.
Haegarda has the latest reference-product exclusivity position among the principal human C1-INH products. Berinert and Cinryze have already passed their 12-year statutory biologic exclusivity periods, but commercial competition remains constrained by the complexity of plasma-derived manufacturing.
What patents protect human C1 esterase inhibitor products?
Protection generally falls into five categories:
- Composition and purified C1-INH material.
- Plasma fractionation and viral inactivation.
- Stabilized formulations.
- Subcutaneous delivery and dosing regimens.
- Methods of treating or preventing HAE attacks.
For biologics, patent protection must be separated from FDA exclusivity. A product can lose reference-product exclusivity while retaining enforceable patents. Conversely, expired patents do not remove manufacturing barriers.
The main technical barriers are often more important than simple composition claims. Plasma-derived products require validated donor screening, pathogen-reduction controls, fractionation, purification, fill-finish and lot-release testing. A competitor must establish a comparable manufacturing chain, not merely copy the active ingredient's amino-acid sequence.
Formulation and delivery protection
Haegarda's commercial differentiation is linked to subcutaneous delivery and routine prophylaxis. Relevant protection can include concentration, excipients, reconstitution, injection volume, dosing intervals and patient self-administration. These claims can matter even after older composition patents expire.
Cinryze's historical protection is more closely tied to intravenous administration, prophylaxis and product-specific manufacturing. Berinert's protection centers on the biologic product, manufacturing controls and acute-treatment use.
Patent scope must be assessed patent by patent. Product labels, FDA approval dates and company annual reports do not provide a complete freedom-to-operate analysis.
What is the Orange Book and Purple Book status?
C1 esterase inhibitor products are biologics licensed under a BLA. They are not conventional small-molecule drugs listed in the FDA Orange Book in the same manner as products approved under an NDA.
The relevant framework is the FDA Purple Book and the Biologics Price Competition and Innovation Act. A follow-on applicant would generally pursue a biosimilar pathway under section 351(k), not an abbreviated new drug application with a conventional Paragraph IV certification.
The practical consequences are:
- No conventional Orange Book patent-listing strategy applies.
- A biosimilar applicant would face the section 351(l) patent-exchange process.
- Interchangeability is a separate regulatory determination.
- The absence of a biosimilar does not mean the reference product lacks patent or manufacturing protection.
Which companies are challenging the human C1-INH franchise?
The most important competitive challengers are not generic manufacturers. They are branded HAE companies with different mechanisms or delivery systems.
| Company |
Product |
Competitive position |
| Takeda |
Takhzyro |
Long-acting subcutaneous prophylaxis |
| BioCryst |
Orladeyo |
Oral prophylaxis |
| Pharming |
Ruconest |
Recombinant acute treatment |
| Takeda |
Firazyr |
Icatibant acute treatment |
| KalVista |
Ekterly, if approved and commercially available in the relevant period |
Oral acute treatment and potential reduction in injectable rescue use |
The competitive risk is highest in prophylaxis, where patients can switch away from intravenous Cinryze or subcutaneous Haegarda. Acute-treatment demand is more fragmented because physicians and patients may retain multiple rescue options.
Are there Paragraph IV challenges or biosimilar risks?
Conventional Paragraph IV litigation is not the primary risk for these BLA products. A generic applicant cannot use the standard ANDA pathway to obtain approval for a biologic C1-INH product.
The more relevant risk is a future biosimilar or interchangeable biosimilar application. As of the cited FDA and company materials, no FDA-approved biosimilar to Berinert, Cinryze or Haegarda had materially altered the U.S. market. Entry would require:
- A sponsor capable of plasma-derived or highly characterized biologic manufacturing.
- Demonstration of analytical similarity and clinical relevance.
- A viable donor-plasma supply chain.
- Resolution of patents through the BPCIA process.
- Sufficient reimbursement access to offset development and manufacturing costs.
A biosimilar could create price pressure, but it would not necessarily produce the rapid erosion associated with small-molecule generic entry.
What litigation and settlement risks affect the market?
The key legal risk is patent or regulatory litigation involving:
- Formulation patents.
- Subcutaneous dosing and administration claims.
- Manufacturing processes.
- Label-scope disputes.
- Biosimilar patent-exchange procedures.
- Exclusivity calculations after BLA supplements or indication expansions.
A conventional Paragraph IV settlement framework is less relevant because these products are not standard Orange Book-listed drugs. No reliable public product-level revenue series or settlement timetable establishes an imminent generic launch for the principal U.S. human C1-INH products.
The lack of a conventional generic pathway supports a slower erosion curve. Competitive displacement is more likely to occur through branded substitution, payer formularies and route-of-administration preferences.
What manufacturing and geographic barriers protect the market?
C1 esterase inhibitor is manufactured from human plasma. The main barriers include donor recruitment, pathogen testing, fractionation capacity, purification yield, cold-chain logistics and regulatory validation.
The geographic market is concentrated in North America and Europe, where diagnosis, specialty reimbursement and emergency-care infrastructure support treatment. Emerging markets have lower diagnosed prevalence and more limited access to high-cost biologics, although diagnosis expansion can create long-term growth.
Supply risk is asymmetric. A shortage or manufacturing interruption can affect the entire category because patients may not be able to switch immediately between products, particularly during acute attacks. CSL's integrated plasma network is a competitive advantage, while manufacturers without direct plasma access face higher input and supply risk.
What generic launch scenarios exist for human C1 esterase inhibitor?
The most probable launch scenarios are:
Branded substitution
This is the leading source of share change. Patients move from Cinryze to Haegarda, Takhzyro or Orladeyo based on administration, payer preference and physician choice.
Biosimilar entry
A biosimilar could emerge after the main exclusivity and patent barriers expire, but the development timeline would be long and manufacturing investment substantial. Initial competition would likely focus on price-sensitive payer segments rather than immediate full-market replacement.
Acute-treatment substitution
Berinert could lose share to icatibant, recombinant C1-INH or oral acute-treatment products. The degree of erosion depends on speed of attack treatment, patient preference and reimbursement.
Formulation-led lifecycle management
New concentrations, delivery devices or dosing schedules can extend commercial life even when basic biologic exclusivity has expired. These changes generally create incremental protection rather than restarting the entire exclusivity period.
How strong is the patent estate and financial outlook?
The patent estate is strongest when product-specific formulation, delivery and manufacturing claims remain enforceable. Composition protection alone is less decisive for a plasma-derived biologic because the manufacturing process and regulatory package are difficult to reproduce.
Financially, the category has a defensive core but weaker growth than newer HAE modalities. Haegarda has the best position among human C1-INH products because it aligns with home-based subcutaneous prophylaxis. Berinert has durable demand in acute treatment. Cinryze faces the clearest long-term pressure because intravenous prophylaxis has become less convenient.
The overall trajectory is likely to be characterized by:
- Stable or modestly growing HAE demand.
- Continued migration from intravenous to subcutaneous or oral prophylaxis.
- Selective price pressure from payer negotiations.
- Limited near-term generic erosion.
- Higher long-term biosimilar and branded-substitution risk.
- Increasing importance of manufacturing reliability and supply continuity.
Key Takeaways
- The principal human C1-INH products are Berinert, Cinryze and Haegarda.
- Haegarda has the strongest growth profile within the category because it provides subcutaneous prophylaxis.
- Cinryze has the greatest commercial exposure to substitution by Takhzyro and Orladeyo.
- Berinert retains a durable role in acute HAE treatment.
- Product-level sales are not separately disclosed by CSL Behring or Takeda.
- Conventional Paragraph IV litigation is not the primary entry mechanism because these are BLA biologics.
- Biosimilar risk is real but constrained by plasma supply, manufacturing complexity and regulatory requirements.
- Market share is more likely to shift through branded competition and payer formularies than through rapid generic substitution.
- The commercial category is mature, with growth concentrated in diagnosis, prophylaxis adoption and route-of-administration improvements.
FAQs
Is C1 esterase inhibitor human a plasma-derived biologic?
Yes. Berinert, Cinryze and Haegarda are manufactured from human plasma and undergo purification and pathogen-control steps. Ruconest is recombinant and is not plasma-derived.
Which C1 esterase inhibitor is used for acute HAE attacks?
Berinert is approved in the U.S. for acute HAE attacks. Ruconest and icatibant are competing acute-treatment products.
Which human C1-INH product has the best commercial outlook?
Haegarda has the strongest outlook among the human C1-INH products because subcutaneous self-administration is more convenient than intravenous prophylaxis. Its main competitors are Takhzyro and Orladeyo.
Can a generic company launch a copy of Berinert through an ANDA?
No. Berinert is a biologic licensed under a BLA. A follow-on product would generally require a 351(k) biosimilar application rather than a conventional ANDA.
Why has Cinryze faced greater commercial pressure than Haegarda?
Cinryze requires intravenous administration for routine prophylaxis. Haegarda is administered subcutaneously, while Takhzyro is dosed less frequently and Orladeyo is taken orally. These alternatives reduce the administration burden for many patients.
References
-
U.S. Food and Drug Administration. (2008). Cinryze prescribing information. FDA.
-
U.S. Food and Drug Administration. (2009). Berinert prescribing information. FDA.
-
U.S. Food and Drug Administration. (2017). Haegarda prescribing information. FDA.
-
U.S. Food and Drug Administration. (2018). Takhzyro prescribing information. FDA.
-
U.S. Food and Drug Administration. (2020). Orladeyo prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023). Purple Book: Database of licensed biological products. FDA.
-
CSL Limited. (2024). Annual report 2024. CSL Limited.
-
Takeda Pharmaceutical Company Limited. (2024). Annual report 2024. Takeda.
-
Maurer, M., Magerl, M., Betschel, S., et al. (2022). The international WAO/EAACI guideline for the management of hereditary angioedema. World Allergy Organization Journal, 15(9), 100627.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, ยงยง 7001-7003.
